KOD - Adverum Biotechnologies: Keep On Your Watchlist In 2020
Today, we will study why Adverum Biotechnologies (ADVM) is a promising gene player in 2020.
Company overview
Adverum Biotechnologies is a clinical-stage gene therapy company focused on ocular and rare diseases. The company is evaluating its lead asset, ADVM-022 in wet AMD (age-related macular degeneration) indication in the Phase 1 trial. Besides, the company is also studying ADVM-022 in diabetic retinopathy indication. Adverum is also studying another gene therapy, AVA-311 in collaboration with Regeneron (REGN) in inherited retinal disease, juvenile XLRS (X-linked Retinoschisis).
How anti-VEGF therapies work in Wet AMD?
According